The healthcare sector is going through a troubling period. However, despite the darkness, there are three glowing stars that investors should keep their watchlists: Pfizer (PFE), Novartis (NVS), and Johnson & Johnson (JNJ).
Don't miss out on Tipranks' six-month sales
The healthcare sector has faced headwinds over the past year, falling by around 8%, while the broader S&P 500 recorded a profit of around 12%. Concerns about regulatory challenges, patent expiration, and changing investor preferences for technology-rich portfolios have contributed to declining sector performance.
However, the long-term foundations of healthcare are strong and the outlook is not dim. Several industry leaders stand out as the sector prepares for potential rebounds. Pfizer, Novartis and Johnson & Johnson each bring clear strengths to the table and are good at playing a central role in the sector's recovery.
Pfizer (NYSE: PFE) | Innovation Meets Revenues
Pfizer stocks have experienced a long-term decline following a decline in vaccine revenues after Covid. However, emotions around the company are beginning to change. Pfizer has made significant advances in AI-driven drug discovery, and strategic partnerships can help accelerate development timelines by up to 25%.
The company's pipeline is attracting attention, particularly for rare diseases such as oncology and myositis. There, new treatments show promising advances. Pfizer is also investing in next-generation therapies, including nanoparticle drug delivery and cytokine-based therapy, placing itself for innovation-driven growth. By navigating well past industry cycles, the company continues to demonstrate a blend of long-term growth potential and operational resilience.
Despite headwinds such as declining sales of Paxlovid and the looming expiration of patents for major drugs like Eliquis, Pfizer expects to provide a stable revenue of $2.90 at the midpoint of guidance. This provides a comfortable support for current dividend yields of 7.1%. Stock trading offers an attractive safety margin for value-oriented investors with approximately eight times the revenue.
Is PFE bought, held or sold?
Currently, most analysts are bullish on PFE stocks. The shares will involve a moderate purchase consensus rating based on five purchases and 13 hold ratings allocated over the past three months. Analysts do not value the stock as selling. PFE's average stock price target is $28.38, meaning it will rise by about 17% over the next 12 months.
Novartis (NYSE: NVS) | Precision Powerhouse
Novartis continues to distinguish between its position as a leading leader in the field of medicine. The 2022 acquisition of Kedalion Therapeutics strengthens its position in ophthalmology through the integration of Acustream technology, reflecting the strategic focus of precision drug delivery.
As a key player in the $7.918 billion target therapy market, which was nearly doubled by 2033, Novartis is treating areas such as cytokine modulation and myositis, bolstering its diversified innovation engine. In particular, stocks are up 13% year-on-year, outperforming the weaker health sector in general.
The company's global footprint adds a further strength to its outlook. Beyond its strong performance in North America, Novartis is actively expanding across Europe and the Asia-Pacific region. Strategic moves like sales to the Chicago manufacturing facility Bristol Myers Squibb demonstrate a continuous focus on operational efficiency and agility. Novartis is supported by its robust R&D pipeline and its emphasis on biology, making it suitable for investors seeking exposure to the rapid expansion of personalized medicine. Meanwhile, even after recent profits on the stock, the dividend yield of 3.3% remains attractive.
Is NVS bought, sold or held?
On Wall Street, Novartis stocks have a hold consensus rating based on two buys, three holds and one selling rating. However, the NVS' average stock price target is $113.05. This means almost 6% downside chances over the next 12 months.
Johnson & Johnson (NYSE: JNJ) | Trustworthy Titan
Johnson & Johnson (JNJ) remains the basis of stability in an uncertain market. The company continues to navigate over 60,000 talc-related lawsuits related to ovarian cancer claims, but the potential settlements could provide much needed clarity and remove significant overhangs from the stock.
In terms of innovation, J&J has made significant advances in areas such as surgical visualization and nanosilicon drug delivery. The two high potential markets are expected to experience significant growth over the next decade. Management projects for the current fiscal year have adjusted earnings per share between $10.50 and $10.70, slightly revised from previous guidance of $10.75 to $10.95. Still, this represents another record year of profitability.
What makes JNJ particularly attractive is its diverse business models spanning consumer health, pharmaceuticals and medical technologies, ensuring stable cash flow across a variety of economic situations. The 63rd consecutive year of uninterrupted dividend increases is a strong indicator of this resilience.
With current dividend yields of 3.4% and the average dividend growth rate over five years is around 5%, the stock offers an attractive income component, especially in a potential rate cut environment. The expected revenue will trade at just 14.3 times. This is below the previous average of 19 times. JNJ appears to be highly praised at today's level.
Is JNJ the right stock to buy?
Johnson & Johnson is currently the subject of 15 Wall Street analysts, half of whom have bullish prospects. The stock has a medium purchase consensus rating, with seven analysts allocating buys and eight assigning holding ratings over the past three months. In particular, Johnson & Johnson's average price target of $171.79 suggests a possible 13% increase over the next 12 months.
Three healthcare giants were ready for a comeback
Despite recent challenges in the healthcare sector, Pfizer, Novartis, Johnson & Johnson are well positioned to lead the next phase of recovery. Pfizer combines sophisticated innovation with strong dividends to make it an attractive option for a balanced portfolio. Novartis stands out as a growth leader focusing on personalized medicine and next-generation therapy. Johnson & Johnson has a diverse business model that provides long-term resilience, even when managing ongoing legal issues.
With the global biopharma market expected to reach $6,400.26 billion this year, these three companies are strategically placed to benefit from the momentum of the new sector. Whether your investment goals prioritize growth, income, or stability, the trio offers a compelling way to gain exposure to evolving future healthcare.
Disclaimer and disclosurereport issues
